SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN), a company specializing in genetic testing and precision medicine with annual revenues of $824 million, has announced the issuance of two ...

Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests – Prolaris Prostate Cancer ...

Myriad Genetics, Inc., a leader in genetic and tumour genomic testing and precision medicine, announced that the United States Patent and Trademark Office (USPTO) issued two new patents that further ...

Myriad Genetics (MYGN) and INTERLINK Care Management announced an agreement designed to enhance education and access to hereditary cancer ...